Aurora Cannabis (US) (TSE:ACB)

NASDAQ:ACB

ACB

Aurora Cannabis

RESEARCH TOOLSreports

Want to see TSE:ACB full AI Analyst Report?

Aurora Cannabis (ACB) Earnings Dates, Call Summary & Reports

Q: When does Aurora Cannabis (US) (TSE:ACB) report earnings?

Aurora Cannabis (US) (TSE:ACB) is schdueled to report earning on Aug 12, 2026, TBA (Confirmed).

Q: What is Aurora Cannabis (US) (TSE:ACB) earnings time?

Aurora Cannabis (US) (TSE:ACB) earnings time is at Aug 12, 2026, TBA (Confirmed).

Q: Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

Q: What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

Q: What is TSE:ACB EPS forecast?

TSE:ACB EPS forecast for the fiscal quarter 2027 (Q1) is -0.13.

1,470 Followers

Earnings Data

Report Date

Aug 12, 2026

TBA (Confirmed)

Period Ending

2027 (Q1)

Consensus EPS Forecast

-0.13

Last Year’s EPS

-0.26

Same Quarter Last Year

Analyst Consensus

Moderate Buy

Based on 3 Analysts Ratings

Earnings Call Summary

Q4 2026

Earnings Call Date:Jun 11, 2026|

% Change Since:

Earnings Call Sentiment|Positive

The call conveyed a predominantly positive operational and financial performance for FY2026 — double-digit revenue growth, strong adjusted gross margins (64%), 32% growth in adjusted EBITDA to CAD 54M, solid international momentum, accretive M&A (Safari) and a strong cash position (CAD 165M, no debt). However, the company signaled a near-term reset driven by a material (~30%) reduction in Canadian reimbursed pricing effective April 1, which will pressure FY2027 revenue, margins (guidance to mid-to-high 50s) and annual adjusted EBITDA despite targeted investments in higher-margin international markets. Overall, strong historic execution and balance sheet strength outweigh the headwinds, but FY2027 is expected to be transitional as management reallocates resources and expands EU GMP capacity.

Company Guidance

For fiscal 2027 Aurora guided that total net revenue is expected to decline (to be more in line with its fiscal‑2025 cannabis net‑revenue level) as the company completes its exit from lower‑margin Canadian consumer and plant‑propagation businesses by end‑September and absorbs an approximate 30% reduction in the reimbursed rate effective April 1; adjusted gross margins are expected in the mid‑to‑high 50s (down from FY2026’s 64% and Q4’s 60%, with medical margin at 66%); adjusted SG&A is expected to be broadly in line with the prior fiscal year (Q4 adj. SG&A CAD 40.3M vs CAD 35.4M prior year); adjusted EBITDA is expected to be lower on an annual basis and more variable quarter‑to‑quarter versus FY2026’s CAD 54M (Q4 adj. EBITDA CAD 9.2M); management will continue to invest in international growth and EU‑GMP capacity (Safari acquisition ~CAD 26.5M; Safari facility 59,000 sq ft; company noted ~40% increase in EU‑GMP capacity over five years and Leuna expansion to double annual flower output in H1 FY2027), and enters the year with CAD 165M of cash and equivalents, no debt, a 25‑month shelf prospectus and an ATM program to issue up to US$100M of common shares.

Record FY2026 Revenue and International Mix

Net revenue rose 11% year-over-year to CAD 321 million in FY2026, exceeding the top end of guidance by CAD 8 million; ~55% of net revenue was generated outside of Canada, reflecting strong international diversification.

Robust Adjusted Margins and EBITDA Growth

Adjusted gross margin improved to 64% for FY2026 and remained industry-leading (60% in Q4); adjusted EBITDA increased 32% year-over-year to CAD 54 million.

Quarterly Strength — Medical Segment Leadership

Fiscal Q4 net revenue increased 10% to CAD 84.8 million. Medical cannabis net revenue rose 14% to CAD 77.1 million (international medical growth +19% in the quarter). Medical comprised 91% of net revenue in Q4.

Strong Balance Sheet and Liquidity Position

Ended the year with approximately CAD 165 million in cash, cash equivalents and short-term investments, no debt, an active shelf prospectus and an at-the-market program (up to US$100M), providing financial flexibility for opportunistic investments.

Strategic M&A and Capacity Expansion

Acquired Safari Flower Company for ~CAD 26.5 million (EU GMP certified); Safari expected to deliver positive adjusted EBITDA in FY2027 with incremental benefits thereafter. EU GMP capacity increased ~40% over the last five years; Leuna expansion expected to double annual flower output when completed in H1 FY2027.

Product and Market Leadership

Aurora positions itself as a leader in Canada, Germany, Australia and Poland; two proprietary cultivars ranked #1 and #3 by sales in Germany this quarter; broadened medical portfolio launches across Canada, Europe, Australia and New Zealand to deepen presence in high-margin regulated markets.

Aurora Cannabis (TSE:ACB) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TSE:ACB Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 12, 2026	2027 (Q1)	-0.13 / -	-0.26	―	―	―
Jun 11, 2026	2026 (Q4)	-0.06 / -0.48	-0.35	-37.14% (-0.13)
Feb 04, 2026	2026 (Q3)	0.13 / 0.03	0.57	-94.74% (-0.54)
Nov 05, 2025	2026 (Q2)	0.02 / -0.91	-0.22	-313.64% (-0.69)
Aug 06, 2025	2026 (Q1)	0.16 / -0.26	0.08	-425.00% (-0.34)
Jun 18, 2025	2025 (Q4)	0.13 / -0.35	-0.4	12.50% (+0.05)
Feb 05, 2025	2025 (Q3)	<0.01 / 0.57	-0.5	214.00% (+1.07)
Nov 06, 2024	2025 (Q2)	-0.11 / -0.22	0	―
Aug 07, 2024	2025 (Q1)	-0.17 / 0.08	-0.8	110.00% (+0.88)
Jun 20, 2024	2024 (Q4)	-0.18 / -0.40	13.626	-102.94% (-14.03)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TSE:ACB Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Jun 11, 2026	C$4.59	C$4.28	-6.75%
Feb 04, 2026	C$5.55	C$5.11	-7.93%
Nov 05, 2025	C$6.42	C$6.29	-2.02%
Aug 06, 2025	C$6.34	C$5.81	-8.36%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.